The first class new drug of Huashen group, ricatin, was selected into the clinical practice guide for liver transplantation of liver cancer in China (2014 Edition)

According to the introduction, the "practice guide" formulated by experts from organ transplantation branch of Chinese Medical Association, transplantation group of branch of external science of Chinese Medical Association and organ transplantation branch of Chinese Medical Association focuses on the following five parts: selection criteria of liver transplantation recipients, pre-operative period reduction treatment, anti-virus treatment of recipients, application of immunosuppressant of recipients, prevention and treatment of postoperative tumor recurrence According to the practice guideline, radioimmunotherapy with iodo [I131] metuximab can reduce the small metastasis and recurrence rate as much as possible, which can provide some survival benefits for some patients Huashen group said that likatine was written into the "China clinical practice guide for liver transplantation of liver cancer (2014)", indicating that the efficacy of iodine [I131] metoximab injection (likatine) in anti recurrence and metastasis after liver transplantation of liver cancer has been recognized by the industry, which provides academic basis for further extensive application of likatine in clinical practice Project: Professor famr Chen Zhinan is mainly engaged in the research of tumor antibody biological drugs, and successfully developed the "iodine [131I] metoximab injection" likatine Through two pharmacological mechanisms of targeted killing and target sealing, the anticancer effect and anti recurrence effect are achieved The new drug showed good efficacy and safety In April 2005, it obtained the first class new drug certificate of national biological products (gyzz s20050039); In October 2006, it obtained the production approval (gyzz s20060064); in January 2007, it passed the GMP certification (i4126); in April, it obtained the production license of radioactive drugs (chuanf200704); in May, it was listed, becoming the first McAb targeting drug with independent intellectual property rights in the world In addition, 60 cases of liver cancer after liver transplantation were treated with the new drug Compared with the control group, the recurrence rate in the treatment group decreased by 30.42%, the survival rate increased by 20.62%, and the negative maintenance rate of AFP was 87.82% Led the establishment of a national pilot cell engineering base with an annual antibody production of kg; A large-scale animal cell culture pilot technology platform of 5L / > - 300L / > has been established, with antibody output of more than 550mg / L, reaching the international advanced level of the same kind In December 2005, it passed the acceptance of the Ministry of science and technology of the people's Republic of China, and the project has been completed well In 2006, it began to cooperate with enterprises to establish a 3000l / > scale engineering cell industrialization technology platform Over the past five years, 48 senior engineering and technical personnel have been trained for 9 universities, scientific research institutions and enterprises.